单管式子宫颈癌后装施源器前瞻性随机对照Ⅱ期临床研究近期疗效

doi:10.3760/cma.j.issn.1004-4221.2018.08.009

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要

目的观察自主研发的单管式子宫颈癌后装施源器与标准Fletcher三管施源器的临床疗效以及安全性。方法选取 2011-2017年就诊的子宫颈癌初诊患者,随机分为外照射+单管式后装组(专利单管组)和外照射+ Fletcher三管式后装组。外照射采用6 MV X线四野盒式或前后对穿野照射,30 Gy后改野挡铅行后装治疗,1 次/周,剂量为A点7 Gy,共 5~6次(A点生物等效剂量:80~90 Gy)。外照射时同步使用顺铂(40 mg/m²)化疗,1 次/周,治疗结束随访其疗效及不良反应并对比。结果符合入组条件并完成治疗,Fletcher三管组 150例,专利单管组 149例。两组近期疗效以及急性期不良反应相近(P>0.05)。Fletcher三管组有效率为94.0%,专利单管组为94.7%。≥3级急性期血液学不良反应,Fletcher三管组为 76例(50.7%),专利单管组为 61例(40.9%)(P=0.195)。结论专利单管式子宫颈癌后装施源器与标准Fletcher三管施源器近期疗效相当,且急性期不良反应相似。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李丹
	文恩
	林盛
	张颖杰
	何丽佳
	任培蓉
	尚昌玲
	向莉
	杨红茹
	张建文
	范娟
	文庆莲
	吴敬波

关键词 ：宫颈肿瘤/近距离疗法, 临床研究

Abstract：

Objective To evaluate whether the self-designed single-channel intracavitary applicator yields equivalent clinical efficacy and safety to the standard Fletcher-type three-channel applicator in the high-dose-rate (HDR) brachytherapy for uterine cervical cancer. Methods From December 2011 to April 2017,patients initially diagnosed with cervical cancer were randomly assigned into the external beam radiotherapy (EBRT)+ single-channel intracavitary applicator group (the patent single-channel group) and EBRT+the Fletcher applicator group. Whole pelvis irradiation was delivered with 6-MV photons via a four-field box variant or anterior and posterior parallel fields. Five to six fractions of intracavitary brachytherapy were performed at a dose of 7 Gy at point A once a week after 30 Gy (BED at point A:80-90 Gy).Chemotherapy was given with intravenous injection of cisplatin at a dose of 40 mg/m² once weekly during EBRT.Clinical efficacy and safety were evaluated after the treatment. Results In total,150 eligible cases were assigned into the Fletcher applicator group and 149 cases into the patent single-channel group. The short-term clinical efficacy and acute toxicity did not significantly differ between two groups. The response rate was 94.0% in the Fletcher group,and 94.7% in the patent single-channel group. In the Fletcher applicator group,76(50.7%) patients developed ≥ grade 3 hematologic toxicity and 61(40.9%) in the patent group (P=0.195). Conclusions The self-designed patent single-channel intracavitary applicator yields equivalent clinical efficacy and safety (acute toxicity) to the standard Fletcher-type three-channel applicator in the HDR brachytherapy for uterine cervical cancer.Clincal Trial Registration Chinese Clinical Trial Registry (ChiCTR-TRC-12002321).

Key words： Uterine cervical neoplasm/brachytherapy Clinical trial

收稿日期: 2017-10-09

通讯作者: 吴敬波,Email:wjb6147@163.com

引用本文:

李丹,文恩,林盛等. 单管式子宫颈癌后装施源器前瞻性随机对照Ⅱ期临床研究近期疗效[J]. 中华放射肿瘤学杂志, 2018, 27(8): 753-758.

Li Dan,Wen En,Lin Shen et al. Evaluation of clinical efficacy and safety of single-channel intracavitary applicator for uterine cervical cancer:early results of a prospective randomized phase Ⅱ clinical trial[J]. Chinese Journal of Radiation Oncology, 2018, 27(8): 753-758.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2018.08.009 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2018/V27/I8/753

[1] Small W Jr,Bacon MA,Bajaj A,et al. Cervical cancer:A global health crisis[J].Cancer,2017,123(13):2404-2412.DOI:10.1002/cncr.30667.
[2] 周晖,刘昀昀,林仲秋.《2017NCCN宫颈癌临床实践指南》解读[J].中国实用妇科与产科杂志,2017,33(1):100-107.DOI:10.19538/j.fk2017010125.
Zhou H,Liu YY,Lin ZQ,et al. Explanations of the NCCN clinical practice guidelines 2017 on cervical cancer[J].Chin J PracGynecol Obstetr,2017,33(1):100-107.DOI:10.19538/j.fk2017010125.
[3] Vordermark D.Radiotherapy of cervical cancer[J].Oncol Res Treat,2016,39(9):516–520.DOI:10.1159/000448902.
[4] Smith GL,Jiang J,Giordano SH,et al. Trends in the quality of treatment for patients with intact cervical cancer in the United States,1999 through 2011[J].Int J Radiat Oncol Biol Phys,2015,92(2):260-267.DOI:10.1016/j.ijrobp.2015.01.037.
[5] Al Feghali KA,Elshaikh MA.Why brachytherapy boost is the treatment of choice for most women with locally advanced cervical carcinoma?[J].Brachytherapy,2016,15(2):191-199.DOI:10.1016/j.brachy.2015.12.003.
[6] Harkenrider MM,Alite F,Silva SR,et al. Image-based brachytherapy for the treatment of cervical cancer[J].Int J Radiat Oncol Biol Phys,2015,92(4):921-934.DOI:10.1016/j.ijrobp.2015.03.010.
[7] Rao PB,Ghosh S.Routine use of ultrasound guided tandem placement in intracavitary brachytherapy for the treatment of cervical cancer-a South Indian institutional experience[J].J Contemp Brachyther,2015,7(5):352-356.DOI:10.5114/jcb.2014.55115.
[8] Watanabe-Nemoto M,Nozaki-Taguchi N,Togasaki G,et al. New approach to relieving pain and distress during high-dose-rate intracavitary irradiation for cervical cancer[J].Brachytherapy,2015,14(5):642-647.DOI:10.1016/j.brachy.2015.04.009.
[9] Nag S,Erickson B,Thomadsen B,et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix[J].Int J Radiat Oncol Biol Phys,2000,48(1):201-211.
[10] 吴敬波.单管式宫颈癌后装施源器[P].中国专利:ZL03233356.0,2004.
Wu JB.A single-channel intracavitary applicator for uterine cervical neoplasms[P].China patent:ZL03233356.0,2004.
[11] 吴敬波.可用于CT扫描的宫颈癌单管式后装施源器[P].中国专利:200720081228.3,2007.
Wu JB.A single-channel intracavitary applicator for uterine cervical neoplasms which can used for CT scanning[P].China patent:200720081228.3,2007.
[12] 吴敬波.可用于CT扫描的宫颈癌单管式后装施源器[P].中国专利:200710050108.1,2007.
Wu JB.A single-channel intracavitary applicator for uterine cervical neoplasms which can used for CT scanning[P].China patent:200710050108.1,2007.
[13] 叶劲军.子宫颈癌单管式后装施源器的临床剂量学研究[D].泸州:泸州医学院,2005.
Ye JJ.Clinical dosimetry study of a single-channel intracavitary applicator which used in cervical cancer[D].Luzhou:Luzhou Medical College,2005.
[14] 刘玉秀,姚晨,陈峰,等.非劣性/等效性试验的样本含量估计及把握度分析[J].中国卫生统计,2004,21(1):31-35.DOI:10.3969/j.issn.1002-3674.2004.01.009.
Liu YX,Yao C,Chen F,et al. Sample size determination and power analysis for noninferiority/equivalence trials[J].Chin J Heal Statist,2004,21(1):31-35.DOI:10.3969/j.issn.1002-3674.2004.01.009.
[15] Suneja G,Brown D,Chang A,et al. American brachytherapy society:brachytherapy treatment recommendations for locally advanced cervix cancer for low-income and middle-income countries[J].Brachytherapy,2017,16(1):85-94.DOI:10.1016/j.brachy.2016.10.007.
[16] Ceting z R,Ataman OU,Tuncel N,et al. Optimization in high dose rate brachytherapy for utero-vaginal applications[J].Radiother Oncol,2001,58(1):31-36.
[17] Basu B,Basu S,Chakraborti B,et al. A comparison of dose distribution from Manchester-style and fletcher-style intracavitary brachytherapy applicator systems in cervical cancer[J].J Contemp Brachyther,2012,4(4):213-218.DOI:10.5114/jcb.2012.32555.
[18] 刘孜,罗伟,王国庆,等.中晚期宫颈癌后装腔内放疗剂量分布影响因素探讨[J].中华放射肿瘤学杂志,2006,15(6):444-447.
Liu Z,Luo W,Wang GQ,et al. Muti-purpose horizontal transit table for influential factors in dose distribution of brachytherapy in moderately advanced uterine cervical cancer[J].Chin J Radiat Oncol,2006,15(6):444-447.
[19] 杨勇琴,王静,张镇君.两种不同腔内后装施源器治疗宫颈癌的临床观察[J].临床肿瘤学杂志,2008,13(12):1115-1118.DOI:10.3969/ j.issn.1009-0460.2008.12.014.
Yang YQ,Wang J,Zhang ZJ.The clinical observation of the treatment of the cervical cancer with two diferent afterloading applicator[J].Chin Clin Oncol,2008,13(12):1115-1118.DOI:10.3969/j.issn.1009-0460.2008.12.014.
[20] 张颖杰.单管式宫颈癌施源器的剂量学研究[D].泸州:泸州医学院,2010.
Zhang YY.Dosimetric study of the single-channel intracavitary applicator[D].Luzhou:Luzhou Medical College,2010.
[21] 吴敬波,殷卓敏,叶劲军,等.宫颈癌单管施源器临床应用的初步观察[C].第六届全国放射肿瘤学学术年会,2007:438-441.
Wu JB,Yin ZM,Ye JJ,et al. The clinical observation of the treatment for the cervical cancer with a single-channel intracavitary applicator[C].The sixth national academic annual meeting on radiation oncology,2007:438-441.
[22] 李爱玲,孙建衡,张蓉,等.子宫颈癌放射治疗 512例临床报告[J].中华妇产科杂志,2000,35(5):303-304.DOI:10.3760/j.issn:0529-567X.2000.05.018.
Li AL,Sun JH,Zhang R,et al. Radiotherapy for cervical cancer:a report of 512 cases[J].Chin J Obstet Gynecol,2000,35(5):303-304.DOI:10.3760/j.issn:0529-567X.2000.05.018.
[23] Devine C,Gardner C,Sagebiel T,et al. Magnetic resonance imaging in the diagnosis,staging,and surveillance of cervical carcinoma[J].Semin Ultrasound CT MR,2015,36(4):361-368.DOI:10.1053/j.sult.2015.05.004.
[24] 余健,张国楠,樊英.同步放化疗治疗中晚期宫颈癌 50 例临床疗效观察[J].实用妇产科杂志,2007,23(5):287-289.DOI:1003-6946(2007)05-287-03.
Yu J,Zhang GN,Fan Y.Curative effect of synchronous radiochemotherapy in medium-term and ad-vanced cervical carcinoma[J].J Prac Obste Gynecol,2007,23(5):287-289.DOI:1003-6946(2007) 05-287-03.
[25] 杜俊瑶,张新,李联崑,等.同步放化疗与单纯放疗治疗中晚期宫颈癌疗效及不良反应比较研究[J].中国实用妇科与产科杂志,2015,31(3):256-260.DOI:1005-2216(2015) 03-0256-05.
Du XY,Zhang X,Li LK,et al. Retrospective study of chemoradiotherapy compared with radiothrepy alone for cervical cancer[J].Chin J PracGynecol Obstetr,2015,31(3):256-260.DOI:1005-2216(2015)03-0256-05.
[26] Kirwan JM,Symonds P,Green JA,et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer[J].Radiother Oncol,2003,68(3):217-226.